Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Grazoprevir/Elbasvir in Treatment-Naïve Chronic HCV GT1, 4, and 6
NCT02105467Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of grazoprevir, elbasvir in hepatitis C (HCV), sponsored by Merck & Co.. Started Jun 2014; status: completed.
02
Drugs
grazoprevirelbasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02105467.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02105467.